✦ LIBER ✦

A phase II study of mitozantrone in advanced carcinoma of the ovary

✍ Scribed by Robert Coleman; Julie Clarke; Martin Gore; Eve Wiltshaw; Maurice Slevin; Peter Harper

Publisher: Springer
Year: 1989
Tongue: English
Weight: 220 KB
Volume: 24
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00300244

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of esorubicin (4′-deozydo

Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary:A Gynecologic Oncology Group study

✍ William P. McGuire; John A. Blessing; Michael L. Berman 📂 Article 📅 1989 🏛 Springer US 🌐 English ⚖ 275 KB

Twenty-six patients with advanced, measurable epithelial carcinoma of the ovary were treated with 76 courses of esorubicin at doses ranging from 20-30 mg/m2 every 3 weeks. All patients are evaluable for toxicity and response. All patients had received prior therapy including radiation therapy in 9,

A phase II study of triazinate (NSC 1391

A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma

✍ Robert H. McCreary; Charles G. Moertel; Alan J. Schutt; Michael J. O'Connell; Ri 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

A Phase II study of irinotecan in patien

A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma

✍ Eileen M. O'Reilly; Keith E. Stuart; Pedro M. Sanz-Altamira; Gary K. Schwartz; C 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

A phase II study of ifosfamide in advanc

A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix

✍ R. E. Coleman; P. G. Harper; C. Gallagher; R. Osborne; E. M. Rankin; A. C. Silve 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 405 KB

Phase II study of pyrazoloacridine in pa

Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma

✍ Mark M. Zalupski; Philip A. Philip; Patricia LoRusso; Anthony F. Shields 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 101 KB

Phase II study of spirogermanium in pati

Phase II study of spirogermanium in patients with advanced colorectal carcinoma

✍ Jaffer A. Ajani; Jack S. Faintuch; Roxann K. McClure; Bernard Levin; Bruce M. Bo 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 193 KB

Twenty one evaluable patients with advanced colorectal carcinoma were treated with continuous infusion of spirogermanium at a median daily dose of 150 mg/rn 2 (range 120-210) for five consecutive days every 14 days. Treatments were accomplished by using outpatient infusion devices. Fifteen patients